• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

David M. Jackman, MD


  • Parikh RB, Cronin AM, Kozono DE, Oxnard GR, Mak RH, Jackman DM, Lo PC, Baldini EH, Johnson BE, Chen AB.Definitive Primary Therapy in Patients Presenting With Oligometastatic Non-Small Cell Lung Cancer.Int J Radiat Oncol Biol Phys. 2014 May 24.
  • Oxnard GR, Paweletz CP, Kuang Y, Mach SL, O'Connell A, Messineo MM, Luke JJ, Butaney M, Kirschmeier P, Jackman DM, Jänne PA.Noninvasive Detection of Response and Resistance in EGFR-Mutant Lung Cancer Using Quantitative Next-Generation Genotyping of Cell-Free Plasma DNA.Clin Cancer Res. 2014 Mar 15;20(6):1698-705.
  • Goldberg SB, Oxnard GR, Digumarthy S, Muzikansky A, Jackman DM, Lennes IT, Sequist LV.Chemotherapy With Erlotinib or Chemotherapy Alone in Advanced Non-Small Cell Lung Cancer With Acquired Resistance to EGFR Tyrosine Kinase Inhibitors.Oncologist. 2013;18(11):1214-20.
  • Nishino M, Dahlberg SE, Cardarella S, Jackman DM, Rabin MS, Ramaiya NH, Hatabu H, Jänne PA, Johnson BE.Volumetric tumor growth in advanced non-small cell lung cancer patients with EGFR mutations during EGFR-tyrosine kinase inhibitor therapy: developing criteria to continue therapy beyond RECIST progression.Cancer. 2013 Nov 1;119(21):3761-8.
  • Nishino M, Dahlberg SE, Cardarella S, Jackman DM, Rabin MS, Hatabu H, Jänne PA, Johnson BE.Tumor volume decrease at 8 weeks is associated with longer survival in EGFR-mutant advanced non-small-cell lung cancer patients treated with EGFR TKI.J Thorac Oncol. 2013 Aug;8(8):1059-68.
  • Nishino M, Cardarella S, Jackman DM, Ramaiya NH, Rabin MS, Hatabu H, Jänne PA, Johnson BE.RECIST 1.1 in NSCLC patients with EGFR mutations treated with EGFR tyrosine kinase inhibitors: comparison with RECIST 1.0.AJR Am J Roentgenol. 2013 Jul;201(1):W64-71.
  • Nishino M, Cardarella S, Dahlberg SE, Jackman DM, Ramaiya NH, Hatabu H, Rabin MS, Jänne PA, Johnson BE.Radiographic assessment and therapeutic decisions at RECIST progression in EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitors.Lung Cancer. 2013 Mar;79(3):283-8.
  • Gaughan EM, Cryer SK, Yeap BY, Jackman DM, Costa DB.Family history of lung cancer in never smokers with non-small-cell lung cancer and its association with tumors harboring EGFR mutations.Lung Cancer. 2013 Mar;79(3):193-7.
  • Oxnard GR, Lo PC, Nishino M, Dahlberg SE, Lindeman NI, Butaney M, Jackman DM, Johnson BE, Jänne PA.Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions.J Thorac Oncol. 2013 Feb;8(2):179-84.
  • Cardarella S, Ortiz TM, Joshi VA, Butaney M, Jackman DM, Kwiatkowski DJ, Yeap BY, Jänne PA, Lindeman NI, Johnson BE.The introduction of systematic genomic testing for patients with non-small-cell lung cancer.J Thorac Oncol. 2012 Dec;7(12):1767-74.
  • Heon S, Yeap BY, Lindeman NI, Joshi VA, Butaney M, Britt GJ, Costa DB, Rabin MS, Jackman DM, Johnson BE.The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutations.Clin Cancer Res. 2012 Aug 15;18(16):4406-14.
  • Evans AG, French CA, Cameron MJ, Fletcher CD, Jackman DM, Lathan CS, Sholl LM.Pathologic characteristics of NUT midline carcinoma arising in the mediastinum.Am J Surg Pathol. 2012 Aug;36(8):1222-7.
  • Nishino M, Cryer SK, Okajima Y, Sholl LM, Hatabu H, Rabin MS, Jackman DM, Johnson BE.Tumoral cavitation in patients with non-small-cell lung cancer treated with antiangiogenic therapy using bevacizumab.Cancer Imaging. 2012;12:225-35.
  • Nishino M, Jackman DM, Hatabu H, Jänne PA, Johnson BE, Van den Abbeele AD.Imaging of lung cancer in the era of molecular medicine.Acad Radiol. 2011 Apr;18(4):424-36.
  • Nishino M, Guo M, Jackman DM, DiPiro PJ, Yap JT, Ho TK, Hatabu H, Jänne PA, Van den Abbeele AD, Johnson BE.CT tumor volume measurement in advanced non-small-cell lung cancer: Performance characteristics of an emerging clinical tool.Acad Radiol. 2011 Jan;18(1):54-62.
  • Heon S, Yeap BY, Britt GJ, Costa DB, Rabin MS, Jackman DM, Johnson BE.Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib.Clin Cancer Res. 2010 Dec 1;16(23):5873-82.
  • Nishino M, Jackman DM, Hatabu H, Yeap BY, Cioffredi LA, Yap JT, Jänne PA, Johnson BE, Van den Abbeele AD.New Response Evaluation Criteria in Solid Tumors (RECIST) guidelines for advanced non-small cell lung cancer: comparison with original RECIST and impact on assessment of tumor response to targeted therapy.AJR Am J Roentgenol. 2010 Sep;195(3):W221-8.
  • Sholl LM, Xiao Y, Joshi V, Yeap BY, Cioffredi LA, Jackman DM, Lee C, Jänne PA, Lindeman NI.EGFR mutation is a better predictor of response to tyrosine kinase inhibitors in non-small cell lung carcinoma than FISH, CISH, and immunohistochemistry.Am J Clin Pathol. 2010 Jun;133(6):922-34.
  • Jackman D, Pao W, Riely GJ, Engelman JA, Kris MG, Jänne PA, Lynch T, Johnson BE, Miller VA.Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.J Clin Oncol. 2010 Jan 10;28(2):357-60.
  • Jackman DM.Current options for systemic therapy in mesothelioma.Semin Thorac Cardiovasc Surg. 2009;21(2):154-8. Review.
  • Jackman DM, Miller VA, Cioffredi LA, Yeap BY, Jänne PA, Riely GJ, Ruiz MG, Giaccone G, Sequist LV, Johnson BE.Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials.Clin Cancer Res. 2009 Aug 15;15(16):5267-73.
  • Souza FF,Jagganathan J,Ramayia N,Johnston C,Jackman D,Abbeele AV,Ros PR.Recurrent malignant peritoneal mesothelioma: radiological manifestations.Abdom Imaging. 2009 Mar 25.
  • Yonesaka K,Zejnullahu K,Lindeman N,Homes AJ,Jackman DM,Zhao F,Rogers AM,Johnson BE,Janne PA.Autocrine production of amphiregulin predicts sensitivity to both gefitinib and cetuximab in EGFR wild-type cancers.Clin Cancer Res. 2008 Nov 1;14(21):6963-73.
  • Costa DB,Nguyen KS,Cho BC,Sequist LV,Jackman DM,Riely GJ,Yeap BY,Halmos B,Kim JH,Janne PA,Huberman MS,Pao W,Tenen DG,Kobayashi S.Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib.Clin Cancer Res. 2008 Nov 1;14(21):7060-7.
  • Cioffredi LA,Janne PA,Jackman DM.Treatment of peritoneal mesothelioma in pediatric patients.Pediatr Blood Cancer. 2009 Jan;52(1):127-9.
  • Jackman DM,Kindler HL,Yeap BY,Fidias P,Salgia R,Lucca J,Morse LK,Ostler PA,Johnson BE,Janne PA.Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma.Cancer. 2008 Aug 15;113(4):808-14.
  • Johnson BE, Jackman D, Jnne PA.Rationale for a phase I trial of erlotinib and the mammalian target of rapamycin inhibitor everolimus (RAD001) for patients with relapsed non small cell lung cancer.Clin Cancer Res. 2007 Aug 1;13(15 Pt 2):s4628-31. Review.
  • Jackman DM, Jnne PA.Does erlotinib improve symptoms in patients with lung cancer?.Nat Clin Pract Oncol. 2007 Mar;4(3):146-7.
  • Jackman DM, Yeap BY, Lindeman NI, Fidias P, Rabin MS, Temel J, Skarin AT, Meyerson M, Holmes AJ, Borras AM, Freidlin B, Ostler PA, Lucca J, Lynch TJ, Johnson BE, Jnne PA.Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer.J Clin Oncol. 2007 Mar 1;25(7):760-6.
  • Jackman DM, Holmes AJ, Lindeman N, Wen PY, Kesari S, Borras AM, Bailey C, de Jong F, Jnne PA, Johnson BE.Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib.J Clin Oncol. 2006 Sep 20;24(27):4517-20.
  • Nakabayashi M, Xie W, Regan MM, Jackman DM, Kantoff PW, Oh WK.Response to low-dose ketoconazole and subsequent dose escalation to high-dose ketoconazole in patients with androgen-independent prostate cancer.Cancer. 2006 Sep 1;107(5):975-81.
  • Jackman DM, Yeap BY, Sequist LV, Lindeman N, Holmes AJ, Joshi VA, Bell DW, Huberman MS, Halmos B, Rabin MS, Haber DA, Lynch TJ, Meyerson M, Johnson BE, Jnne PA.Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib.Clin Cancer Res. 2006 Jul 1;12(13):3908-14.
  • Jackman DM, Johnson BE.Small-cell lung cancer.Lancet. 2005 Oct 15-21;366(9494):1385-96.
  • Jackman DM, Chirieac LR, Jnne PA.Bronchioloalveolar carcinoma: a review of the epidemiology, pathology, and treatment.Semin Respir Crit Care Med. 2005 Jun;26(3):342-52.